On October 6, 2025, Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, entered into a Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc. This agreement, which supersedes a previous interim agreement from February 2022, involves the manufacturing and supply of ciltacabtagene autoleucel (cilta-cel) for clinical and commercial use globally, excluding Greater China. The agreement outlines the shared costs and responsibilities between Legend Biotech and Janssen, including the supply of raw materials and the handling of production costs. This strategic partnership is expected to enhance Legend Biotech’s operational capabilities and strengthen its position in the global biotechnology market.
Legend Biotech Corporation is a prominent player in the biotechnology industry, focusing on the development and commercialization of innovative cell therapies. The company is known for its work in the field of oncology, particularly in the manufacturing and supply of CAR-T cell therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.